IP Library › Granted Patent US 8,178,690
Granted Patent B2
US 8,178,690 · App. 13/089,530 · Granted May 15, 2012

Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Assignee: Infinity Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,690
App. No.
13/089,530
Granted
May 15, 2012
Kind
B2
Abstract

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Claims (15)

1. A compound selected from the group consisting of:

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is selected from the group consisting of:

4. The compound of claim 1 , wherein the compound is selected from the group consisting of:

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

6. A compound selected from the group consisting of:

7. The compound of claim 6 , wherein the compound is selected from the group consisting of:

8. The compound of claim 6 , wherein the compound is selected from the group consisting of:

9. The compound of claim 6 , wherein the compound is selected from the group consisting of:

10. The compound of claim 6 , wherein the compound is selected from the group consisting of:

11. A compound selected from the group consisting of:

12. The compound of claim 11 , wherein the compound is selected from the group consisting of:

13. The compound of claim 11 , wherein the compound is selected from the group consisting of:

14. The compound of claim 11 , wherein the compound is selected from the group consisting of:

15. The compound of claim 11 , wherein the compound is selected from the group consisting of:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2012
From: CASTRO, ALFREDO C.; DEPEW, KRISTOPHER M.; GROGAN, MICHAEL J.; JOHANNES, CHARLES W.; HOLSON, EDWARD B.; HOPKINS, BRIAN T.; KEANEY, GREGG F.; KONEY, NII O.; LIU, TAO; MANN, DAVID A.; NEVALAINEN, MARTA; PELUSO, STEPHANE; PEREZ, LAWRENCE BLAS; SNYDER, DANIEL A.; TIBBITTS, THOMAS T.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 027818/0707 →
Continuity (3)
Continuation 11842581 · Aug 21, 2007
Provisional Application 60838987 · Aug 21, 2006
Related Publication 20110213145A1 · Sep 1, 2011